Compare VRE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRE | IVA |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1994 | 2020 |
| Metric | VRE | IVA |
|---|---|---|
| Price | $14.75 | $6.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $18.67 | $16.00 |
| AVG Volume (30 Days) | 592.8K | ★ 602.4K |
| Earning Date | 02-23-2026 | 09-29-2025 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $291,348,000.00 | $19,929,536.00 |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.79 | ★ N/A |
| Revenue Growth | ★ 6.39 | N/A |
| 52 Week Low | $13.69 | $2.15 |
| 52 Week High | $17.18 | $7.98 |
| Indicator | VRE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 72.20 |
| Support Level | $14.61 | $6.76 |
| Resistance Level | $15.23 | $7.29 |
| Average True Range (ATR) | 0.32 | 0.35 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 29.26 | 82.41 |
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.